Age-related and fibrotic disease deserve better treatments
Lung fibrosis affects millions of people a year. Despite this global burden, current therapeutic approaches manage the downstream symptoms of these diseases.
What current treatments miss is that all these diseases share a fundamental pathobiology: the accumulation of senescent cells. As the body ages, these cells secrete inflammatory factors into the surrounding tissue, causing fibrotic scarring. This in turn blocks the body’s natural ability to clear ageing cells.
Our goal is to provide upgrades for the immune system to counteract age-related tissue decline.
A computational platform that maps the surfaceome of fibrotic tissues
The historical barrier to the effective treatment of age-related and fibrotic disease has been a lack of precision.
Neotis has developed a proprietary computational platform that maps the cell surface proteins unique to ageing and damaged tissues.
By analysing thousands of transcriptomic samples and dozens of single-cell datasets across multiple organ types, our bioinformatics platform identifies highly specific transmembrane targets unique to ageing and damaged tissues.
Redirecting the immune system to target senescent cells
As a result of this mapping, our therapies can engage dangerous cells with much greater specificity than traditional approaches, preserving healthy tissue in the process.
Once identified, these tissues are pin-pointed using proven targeting modalities from immuno-oncology. Neotis redirects the body’s cytotoxic T-cells straight to pathogenic senescent cells.
Our therapeutics thus function as a physical bridge between the body’s own natural immune system and its ageing cells.
